

# Stuart M Sprague

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3990129/publications.pdf>

Version: 2024-02-01

72  
papers

3,505  
citations

147801

31  
h-index

133252

59  
g-index

77  
all docs

77  
docs citations

77  
times ranked

2630  
citing authors

#	ARTICLE	IF	CITATIONS
1	Abnormalities in Cardiac Structure and Function among Individuals with CKD: The COMBINE Trial. <i>Kidney360</i> , 2022, 3, 258-268.	2.1	5
2	Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence. <i>Journal of Nephrology</i> , 2022, 35, 875-888.	2.0	5
3	Small Intestinal Phosphate Absorption: Novel Therapeutic Implications. <i>American Journal of Nephrology</i> , 2021, 52, 522-530.	3.1	7
4	ESKD Complications: CKD-MBD. , 2021, , 211-231.		0
5	Phosphate Balance and CKDâ€™Mineral Bone Disease. <i>Kidney International Reports</i> , 2021, 6, 2049-2058.	0.8	22
6	A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1463-1472.	2.4	3
7	A Randomized Trial Comparing the Safety, Adherence, and Pharmacodynamics Profiles of Two Doses of Sodium Bicarbonate in CKD: the BASE Pilot Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 161-174.	6.1	42
8	The Enigma of Vascular Calcifications. <i>Kidney International Reports</i> , 2020, 5, 2127-2129.	0.8	1
9	Kidney Functional Magnetic Resonance Imaging and Change in eGFR in Individuals with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 776-783.	4.5	27
10	Secondary Hyperparathyroidism in a Patient with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1041-1043.	4.5	7
11	Interventions for Preventing Bone Disease Following Kidney Transplantation: Is There Evidence for Specific Therapy?. <i>American Journal of Kidney Diseases</i> , 2020, 75, 809-811.	1.9	2
12	Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study. <i>Nephron</i> , 2020, 144, 428-439.	1.8	2
13	Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 946-954.	0.7	3
14	Medullary Blood Oxygen Level-Dependent MRI Index (R2*) is Associated with Annual Loss of Kidney Function in Moderate CKD. <i>American Journal of Nephrology</i> , 2020, 51, 966-974.	3.1	16
15	Parathyroid Hormone as a Uremic Toxin. , 2020, , 143-149.		0
16	Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney diseaseâ€™mineral bone disorder parameters in dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1163-1170.	0.7	28
17	Cortical Perfusion and Tubular Function as Evaluated by Magnetic Resonance Imaging Correlates with Annual Loss in Renal Function in Moderate Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2019, 49, 114-124.	3.1	42
18	Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1096-1108.	6.1	83

#	ARTICLE	IF	CITATIONS
19	Management of Bone Disorders in Kidney Disease. , 2019, , 231-242.		0
20	Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease. American Journal of Nephrology, 2019, 49, 284-293.	3.1	51
21	Consistency of Multiple Renal Functional MRI Measurements Over 18 Months. Journal of Magnetic Resonance Imaging, 2018, 48, 514-521.	3.4	4
22	Should phosphate management be limited to the KDIGO/ KDOQI guidelines?. Seminars in Dialysis, 2018, 31, 377-381.	1.3	6
23	FP152EFFECT OF BARDOXOLONE METHYL TREATMENT ON URINARY ALBUMIN IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE - POST-HOC ANALYSIS FROM BEAM AND BEACON. Nephrology Dialysis Transplantation, 2018, 33, i27-i27.	0.7	2
24	Mineral and Bone Disease in Kidney Transplant Recipients. Current Osteoporosis Reports, 2018, 16, 703-711.	3.6	16
25	SP104DECREASES IN WEIGHT WITH BARDOXOLONE METHYL IN OBESE PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 4 AND TYPE 2 DIABETES - POST-HOC ANALYSES FROM BEACON. Nephrology Dialysis Transplantation, 2018, 33, i379-i379.	0.7	2
26	Multicenter Study Evaluating Intrarenal Oxygenation and Fibrosis Using Magnetic Resonance Imaging in Individuals With Advanced CKD. Kidney International Reports, 2018, 3, 1467-1472.	0.8	13
27	Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opinion on Pharmacotherapy, 2018, 19, 1137-1148.	1.8	9
28	Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrology Dialysis Transplantation, 2017, 32, gfw242.	0.7	32
29	Imaging in Chronic Kidney Diseaseâ€”Metabolic Bone Disease. Seminars in Dialysis, 2017, 30, 361-368.	1.3	12
30	Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Expert Review of Endocrinology and Metabolism, 2017, 12, 289-301.	2.4	24
31	Evaluation of Renal Blood Flow in Chronic Kidney Disease Using Arterial Spin Labeling Perfusion Magnetic Resonance Imaging. Kidney International Reports, 2017, 2, 36-43.	0.8	51
32	Perspective and priorities for improvement of parathyroid hormone (PTH) measurement â€” A view from the IFCC Working Group for PTH. Clinica Chimica Acta, 2017, 467, 42-47.	1.1	46
33	One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrology Dialysis Transplantation, 2017, 32, 1918-1926.	0.7	21
34	Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease. American Journal of Nephrology, 2016, 44, 316-325.	3.1	80
35	We Do Too Many Parathyroidectomies for Calciphylaxis. Seminars in Dialysis, 2016, 29, 312-314.	1.3	19
36	Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low. Journal of Nephrology, 2016, 29, 63-70.	2.0	33

#	ARTICLE	IF	CITATIONS
37	Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. <i>American Journal of Kidney Diseases</i> , 2016, 67, 559-566.	1.9	218
38	Renal Blood Oxygenation Level-Dependent Magnetic Resonance Imaging. <i>Investigative Radiology</i> , 2015, 50, 821-827.	6.2	25
39	Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2328-2339.	6.1	116
40	A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1031-1040.	4.5	70
41	Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1021-1030.	4.5	65
42	FP397POST HOC ANALYSIS OF IRON INDICES IN DIALYSIS PATIENTS WITH LOWER VS HIGHER BASELINE FERRITIN IN A PHASE 3 STUDY OF SUCROFERRIC OXYHYDROXIDE. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii202-iii202.	0.7	0
43	Multi-Parametric Evaluation of Chronic Kidney Disease by MRI: A Preliminary Cross-Sectional Study. <i>PLoS ONE</i> , 2015, 10, e0139661.	2.5	56
44	A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. <i>Kidney International</i> , 2014, 86, 638-647.	5.2	154
45	Cinacalcet hydrochloride for the treatment of hyperparathyroidism. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 851-863.	0.8	0
46	Painful Skin Ulcers in a Hemodialysis Patient. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 166-173.	4.5	34
47	Modified-Release Calcifediol Effectively Controls Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2014, 40, 535-545.	3.1	48
48	A Randomized Multicenter Trial of Paricalcitol versus Calcitriol for Secondary Hyperparathyroidism in Stages 3&4 CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1620-1626.	4.5	62
49	CKDâ€“Mineral and Bone Disorder Management in Kidney Transplant Recipients. <i>American Journal of Kidney Diseases</i> , 2013, 61, 310-325.	1.9	61
50	Rebuttal. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 321.	4.5	9
51	The Case for Routine Parathyroid Hormone Monitoring. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 313-318.	4.5	32
52	Is bone mineral density measurement of any value in a dialysis patient?. <i>Seminars in Dialysis</i> , 2011, 24, 433-434.	1.3	4
53	Renal bone disease. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2010, 17, 535-539.	2.3	21
54	KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKDâ€“Mineral and Bone Disorder (CKD-MBD). <i>American Journal of Kidney Diseases</i> , 2010, 55, 773-799.	1.9	231

#	ARTICLE	IF	CITATIONS
55	Control of Secondary Hyperparathyroidism by Vitamin D Receptor Agonists in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 512-518.	4.5	37
56	Lanthanum Carbonate Reduces Phosphorus Burden in Patients with CKD Stages 3 and 4. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 178-185.	4.5	86
57	Bone Disease in Kidney Transplant Patients. <i>Seminars in Nephrology</i> , 2009, 29, 166-173.	1.6	7
58	Abnormal Bone and Mineral Metabolism in Kidney Transplant Patients – A Review. <i>American Journal of Nephrology</i> , 2008, 28, 246-253.	3.1	71
59	A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. <i>Current Medical Research and Opinion</i> , 2007, 23, 3167-3175.	1.9	65
60	Impact of Ergocalciferol Treatment of Vitamin D Deficiency on Serum Parathyroid Hormone Concentrations in Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2007, 27, 36-43.	3.1	171
61	Treatment of renal osteodystrophy. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2007, 5, 27-38.	0.8	2
62	Paricalcitol Capsule for the Treatment of Secondary Hyperparathyroidism in Stages 3 and 4 CKD. <i>American Journal of Kidney Diseases</i> , 2006, 47, 263-276.	1.9	198
63	Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. <i>American Journal of Kidney Diseases</i> , 2004, 43, 877-890.	1.9	152
64	Bone disease after kidney transplantation. <i>Seminars in Nephrology</i> , 2004, 24, 82-90.	1.6	68
65	Calcium and Calcitriol Prophylaxis Attenuates Posttransplant Bone Loss. <i>Transplantation</i> , 2004, 78, 1233-1236.	1.0	86
66	Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. <i>Kidney International</i> , 2003, 63, 1483-1490.	5.2	331
67	Effect of a Low Calcium Dialysate on Parathyroid Hormone Secretion in Diabetic Patients on Maintenance Hemodialysis. <i>Journal of Bone and Mineral Research</i> , 2000, 15, 927-935.	2.8	24
68	Increased Risk of Fracture in Patients Receiving Solid Organ Transplants. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 456-463.	2.8	225
69	The effect of 24,25 dihydroxyvitamin D3 on calcium efflux: The role of protein kinase C. <i>Nephrology</i> , 1998, 4, 157-162.	1.6	4
70	Effects of aluminum on bone surface ion composition. <i>Journal of Bone and Mineral Research</i> , 1995, 10, 1988-1997.	2.8	41
71	<b>Aluminum: Its Measurement and Metabolism</b>. <i>Seminars in Dialysis</i> , 1988, 1, 103-111.	1.3	2
72	Determinants of Tissue Aluminum Concentration. <i>American Journal of Kidney Diseases</i> , 1981, 1, 141-145.	1.9	13